首页>
外国专利>
QUANTITATIVE CENTROSOMAL AMPLIFICATION SCORE TO PREDICT LOCAL RECURRENCE OF DUCTAL CARCINOMA IN SITU
QUANTITATIVE CENTROSOMAL AMPLIFICATION SCORE TO PREDICT LOCAL RECURRENCE OF DUCTAL CARCINOMA IN SITU
展开▼
机译:定量中央放大,预测原位癌的局部复发
展开▼
页面导航
摘要
著录项
相似文献
摘要
Embodiments may provide capability to predict the 10-year risk of local recurrence of ductal carcinoma in situ (DCIS) conditions or other non-invasive carcinomas in situ. Embodiments may evaluate the severity and frequency of numerical and structural CA present within DCIS, and may assign a quantitative centrosomal amplification score (CAS) to each sample. For example, a method of determining the risk profile of a carcinoma in situ in a patient may comprise determining severity and frequency of numerical and structural centrosome amplification present within a sample of a carcinoma in situ from the patient and determining at least one centrosome amplification score (CAS) value for the sample based on the determined severity and frequency of numerical and structural centrosome amplification in the sample, wherein the determined at least one CAS value provides a measure of a level of a 10-year risk of local recurrence associated with the carcinoma in situ.
展开▼